XenoPort Inc.

D. Byron Miller has been our vice president and chief patent counsel since April 2002. From 1988 to 2002, he held various positions at Alza Corporation, the most recent of which was assistant secretary and director of intellectual property. Prior to joining Alza, Mr. Miller was an associate at Banner, Birch, McKie and Beckett in Washington, D.C. He received a B.S. degree from the University of Pennsylvania and a J.D. degree from Rutgers University.

William J. Dower is one of our founders and has been our vice president of discovery biology since 1999. From 1989 to 1999, he held various positions at Affymax Research Institute, the most recent of which was senior director of molecular biology. Prior to Affymax Research Institute, Dr. Dower held the position of senior research biochemist at Bio-Rad Laboratories, Inc., from 1984 to 1989. He received his B.A. and Ph.D. degrees in biological sciences from the University of California, San Diego.

Scott Minick is a Managing Director with ARCH, joining the firm as a Venture Partner in 1998. Mr. Minick has been instrumental in the startup, development and financing of numerous portfolio companies including XenoPort (XNPT), FastTrack Systems, MedVantx, Achaogen, Amphora Discovery, Celula, Ensemble Discovery, and Sorbent Therapeutics. He serves as a board director for Achaogen, Amphora Discovery, Celula, FastTrack Systems, Optobionics and Sorbent Therapeutics. Mr. Minick currently serves as Chairman of the Board for MedVantx and formerly served as Chairman of Xcyte Therapies (XCYT) through its IPO in 2004 and subsequent acquisition of Cyclacel Pharmaceuticals (CYCL). He also previously served as Executive Chairman of Amphora Discovery. From 1995 until 1998, Mr. Minick was director, President and COO of SEQUUS Pharmaceuticals, a public biopharmaceutical company that was acquired by GlaxoSmithKline. From 1994 to 1995, he served as a director, President and CEO of OncoTherapeutics, a private biotechnology company. Prior to that, Mr. Minick co-founded and was a director, President and CEO of LXR Biotechnology from startup through its IPO. From 1981 to 1993, he was an executive of Baxter Healthcare, holding leadership positions in the device, service and diagnostics businesses. He received his postgraduate training in neurobiology at the Salk Institute, an M.B.A. from Northwestern University and a B.A. with Honors from the University of California at San Diego.